Invesco
OVID icon

Invesco’s Ovid Therapeutics OVID Stock Holding History

Invesco’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$226K Buy
101,581
+68,273
+205% +$122K ﹤0.01% 3442
2025
Q4 		$54.3K Buy
+33,308
New +$51.3K ﹤0.01% 3699
2025
Q2 		– Sell
-27,207
Closed -$8.49K – 3837
2025
Q1 		$8.49K Hold
27,207
– – ﹤0.01% 3758
2024
Q4 		$25.4K Sell
27,207
-2,130
-7% -$2.38K ﹤0.01% 3733
2024
Q3 		$34.6K Buy
29,337
+487
+2% +$509 ﹤0.01% 3721
2024
Q2 		$22.2K Sell
28,850
-704
-2% -$1.96K ﹤0.01% 3863
2024
Q1 		$90.1K Sell
29,554
-331
-1% -$1.11K ﹤0.01% 3757
2023
Q4 		$96.2K Buy
29,885
+6,898
+30% +$23.6K ﹤0.01% 3692
2023
Q3 		$88.3K Hold
22,987
– – ﹤0.01% 3735
2023
Q2 		$75.4K Buy
+22,987
New +$78.1K ﹤0.01% 3769
2021
Q2 		– Sell
-11,254
Closed -$45K – 4012
2021
Q1 		$45K Buy
+11,254
New +$37.4K ﹤0.01% 3836
2020
Q3 		– Sell
-675,900
Closed -$4.98M – 3676
2020
Q2 		$4.98M Buy
+675,900
New +$3.16M ﹤0.01% 1995

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Invesco's OVID Position: Q1 2026 in Review

Invesco increased its Ovid Therapeutics (OVID) stake by 205% in Q1 2026, buying an estimated $122K and bringing the position to 101,581 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #3442.

Invesco first reported a position in OVID in Q2 2020 and has held it in 12 quarters since. The position peaked at $4.98M in Q2 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Invesco held 101,581 shares of Ovid Therapeutics worth $226K as of Q1 2026.
  • Invesco bought 68,273 Ovid Therapeutics shares in Q1 2026, an estimated $122K.
  • Ovid Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3442 holding.
  • Invesco first reported a position in Ovid Therapeutics in Q2 2020 and has held it in 12 quarters since.
  • Invesco's Ovid Therapeutics position peaked at $4.98M in Q2 2020.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.